ESG risk score -
Environmental score -
Social score -
Governance score -
ESG risk category -
Negligible Low Med High Severe
0-10 10-20 20-30 30-40 40+
Kalaris Therapeutics Inc
000.00
0.00 / 0.00%
00:00:00
52 week range
0000.00 000.00
Symbol KLRS:xnas
Currency USD
NASDAQ
Open Closed
15 minutes delayed
Data provided by 
This information is not currently available for this instrument. Refresh the page or try again later.
Want to start investing?
Trade stocks with a broker trusted by over 1.5 million clients. Investing involves risk. You may lose some or all of your investment.
Chart
This information is not currently available for this instrument. Refresh the page or try again later.
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer.
Quotes
- Bid
- Ask
- Open
- Previous close
- Volume
- Relative volume
- High
- Low
This information is not currently available for this instrument. Refresh the page or try again later.
Returns
Year to date (YTD) -25.71%
1 year -11.44%
3 years -92.83%
Data provided by 
Key stats
Price/earnings (LTM) -
Dividend yield (LTM) -
EPS (LTM) -4.2
Volatility (30 days) 79.83%
Data provided by
ESG risk
ESG risk is a measure of how well a company manages material ESG risks. Sustainalytics’ ESG risk category is designed to help investors identify and understand financially material ESG risks at the company level and how they might affect the long-term performance for equity investments. The scale is from 0-100. The lower the risk, the better (0 is equivalent to no risk and 100 the most severe).
Download ESG risk methodology (PDF)Data provided by 
/ 
/ Financials
Q1 Q2 Q3 Q4
Income statement
Revenue XXXXXXX XXXXXXX XXXXXXX XXXXXXX
EBITDA XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Net income XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Balance sheet
Total assets XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Total debt XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Ratios
Price/sales XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Earnings per share XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Dividend per share XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Return on equity XXXXXXX XXXXXXX XXXXXXX XXXXXXX
About Kalaris Therapeutics Inc
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
Sector Healthcare
Industry -
Market cap 0.148116818bn
Data provided by /
/ Frequently asked questions
To buy Kalaris Therapeutics Inc stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Kalaris Therapeutics Inc by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Kalaris Therapeutics Inc is KLRS:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Kalaris Therapeutics Inc has its primary listing on NASDAQ. You can trade Kalaris Therapeutics Inc with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Kalaris Therapeutics Inc is available to trade on SaxoInvestor and SaxoTrader. You can buy shares directly and include Kalaris Therapeutics Inc as part of a broader investment portfolio.